This technology is a composition for inhibiting prostate cancer metastasis containing Gleditsia sinensis thorn extract as an active ingredient. It selectively reduces the expression of the collagen receptor α2β1 integrin, specifically weakening the process by which prostate cancer cells adhere to and migrate along collagen. This composition can be formulated as an anticancer agent for inhibiting prostate cancer metastasis or as a food composition for preventing or improving metastasis.
Prostate cancer is a leading cause of cancer-related death in men, yet androgen deprivation therapy, prostatectomy, and radiation therapy have been ineffective at preventing metastasis, leading to high mortality rates. Most existing anticancer drugs focus on inhibiting cancer cell proliferation, and previous research on Gleditsia sinensis thorns has also been limited to inhibiting the growth of stomach, colon, and lung cancers, leaving a gap in natural materials specifically targeting the metastasis stage itself.
This technology utilizes a water extract obtained by hot-water extraction, filtration, concentration, and freeze-drying of Gleditsia sinensis thorns. It is designed to inhibit collagen I-mediated intracellular FAK phosphorylation signals in PC3 prostate cancer cells, thereby blocking both adhesion and migration. The scope of the rights includes oral administration at levels that do not exhibit cytotoxicity. It can be applied as an adjuvant anticancer agent for inhibiting metastasis in prostate cancer patients, a health functional food for preventing metastasis, or a natural candidate for developing integrin-targeted anti-metastatic drugs, allowing for the selective blockage of collagen adhesion and migration—the core stages of cancer metastasis—at low concentrations that do not harm normal cells.
N/A
